Effects of Oxytocin on Reinforcement Learning

Study Overview
=================
Brief Summary
-----------------
The main aim of the study is to investigate whether intranasal oxytocin (24IU) influences reward sensitivity and performance monitoring during reinforcement learning.

Detailed Description
-----------------
A double-blind, within-subject, placebo-controlled pharmacological EEG design will be employed. A total of 35 healthy male subjects will be recruited which will receive either intranasal placebo or oxytocin (24IU) on two separate study days (order counter-balanced, washout period at least 2 weeks). 45 minutes after treatment subjects will undergo a probabilistic feedback reinforcement learning paradigm with concurrent EEG acquisition. During the paradigm subjects will learn the reward probabilities of two different visual stimuli from probabilistic feedback provided by social stimuli (positive, negative emoticon). The paradigm includes an initial acquisition phase and a subsequent test phase.

Official Title
-----------------
The Effects of Intranasal Oxytocin on Reward Sensitivity and Performance Monitoring During Reinforcement Learning: an ERP Study

Conditions
-----------------
Learning Disabilities

Intervention / Treatment
-----------------
* Drug: intranasal oxytocin
* Drug: intranasal placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 18-30 Male sex Right handedness Exclusion Criteria: History of brain injury Current or history of psychiatric, neurological or internist disorder Current or regular use of medication, psychotropic substances, including nicotine Contraindications for Oxytocin

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Interventional Model Description: Randomized placebo-controlled double-blind within-subject design
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Oxytocin then placebo<br>Participants first receive oxytocin (24 IU). After a washout period of 2 weeks, they receive placebo. | Drug: intranasal oxytocin<br>* 24 IU of oxytocin nasal spray will be applied to each subject.<br>Drug: intranasal placebo<br>* an identical amount of placebo nasal spray will be applied to each subject.<br>|
| Experimental: Placebo then oxytocin<br>Participants first receive placebo. After a washout period of 2 weeks, they receive oxytocin (24 IU). | Drug: intranasal oxytocin<br>* 24 IU of oxytocin nasal spray will be applied to each subject.<br>Drug: intranasal placebo<br>* an identical amount of placebo nasal spray will be applied to each subject.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neural index: Event-related potential: Feedback Related Negativity (FRN) during acquisition phase | Feedback Related Negativity (FRN): a negative ERP component evoked by negative feedback relative to positive feedback during the acquisition phase will be compared between the oxytocin and placebo treatment conditions. | 45-105 minutes after treatment administration | 
| Neural index: Event-related potential: Error Related Negativity (ERN) during the test phase | Error Related Negativity (ERN): a negative ERP component evoked by incorrect responses relative to correct responses during the test phase will be compared between the oxytocin and placebo treatment conditions. | 45-105 minutes after treatment administration | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Behavioral index: Response accuracy to superior stimuli during the acquisition phase | Correct responses are defined as choices of the stimulus associated with higher probability positive feedback during the acquisition phase. Effects of treatment will be analyzed by comparing the performance between the two treatment conditions. | 45-105 minutes after treatment administration | 
| Behavioral index: Response accuracy to stimuli associated with highest probability positive feedback during the test phase | Correct responses are defined as choices of the stimulus associated with highest probability positive feedback as learned in the acquisition phase. Effects of treatment will be analyzed by comparing the performance between the two treatment conditions. | 45-105 minutes after treatment administration | 
| Response accuracy avoiding stimuli associated with highest probability negative feedback in the test phase. | Correct responses are defined as avoidance choices of stimuli associated with highest probability negative feedback as learned in the acquisition phase. Effects of treatment will be analyzed by comparing the performance between the two treatment conditions. | 45-105 minutes after treatment administration | 
| Response accuracy in response to superior stimuli associated with relative higher probability positive feedback in the test phase. | Correct responses are defined as choices of the stimulus associated with higher probability positive feedback. Note that stimuli pairs in this measurement are all associated with positive feedback. Effects of treatment will be analyzed by comparing the performance between the two treatment conditions. | 45-105 minutes after treatment administration | 
| Response accuracy avoiding stimuli associated with higher probability negative feedback in the test phase. | Correct responses are defined as avoidance choices of stimuli associated with higher probability negative feedback. Note that stimuli pairs in this measurement are all associated with negative feedback. Effects of treatment will be analyzed by comparing the performance between the two treatment conditions. | 45-105 minutes after treatment administration | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Oxytocin, performance monitoring, reinforcement learning